KONEXFood & Beverage289170

Bioten

₩2,780▲ 13.70%2026-11-18 close
Market Cap
₩9.9B
Turnover
₩2,780
Volume
1 shares
Shares out.
3.6M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Bioten: Losses Persist in a KONEX Small-Cap

Bioten has recorded net losses in each year from 2023 to 2025 as sales fell, while its natural-product materials business and licensed pipeline remain the core of its strategy.

  1. 1

    On a 2025 basis, sales were KRW 3,749 million and operating loss was KRW 905 million, so the company has remained loss-making since its 2022 profit.

  2. 2

    Sales dropped from above KRW 10.7 billion in 2022 to the KRW 5.4 billion range in 2023, held near that level in 2024, and then fell to KRW 3.7 billion range in 2025.

  3. 3

    The company licensed technology from KRIBB and signed technology transfer agreements covering anti-obesity and colorectal cancer compositions in 2024.

  4. 4

    As of 2022, a single principal customer accounted for more than 85% of total sales, indicating high customer concentration.

  5. 5

    After being designated a concentrated small-account trading stock in October 2024, the share price has been volatile, and the current price is well below the KRW 8,000 listing reference price.

02

Business structure

Bioten, founded in October 2010, develops bio-pharmaceutical materials through joint research and technology transfer agreements with the Korea Research Institute of Bioscience and Biotechnology (KRIBB), with its core technology being a method that makes poorly soluble natural substances usable (WIN-T).

Its main products are functional materials derived from natural products, applied to human pharmaceuticals and quasi-drugs, health functional foods, and animal drugs and quasi-drugs.

As of an October 2023 news report, the company produced nine health functional food products, including TENQmin S and TENQmin G Plus, and 26 animal feed supplement products.

Its own health food brand TENQmin was launched in March 2023 targeting the United States, China, Vietnam and Central Asia, and four overseas MOUs were reported that year.

In 2024, technology transfer licensing agreements were signed for an anti-obesity composition in June and a colorectal cancer prevention and treatment composition in July, and a colorectal cancer clinical trial for TENQmin S Plus received IRB approval from Konyang University.

Production capacity was expanded through the purchase of a second plant in Yeonggwang in June 2024 and the completion of a new Jeongeup plant with headquarters relocation in August 2025. Customer concentration is high, as a single principal customer accounted for more than 85% of total sales as of 2022.

Compared with large food companies, its production scale and distribution network are smaller. The company had 17 employees according to National Pension Service data cited by Saramin.

03

Recent trends

Sales in 2022 were KRW 10,705 million, with operating profit of KRW 1,777 million and net profit of KRW 880 million. In 2023, sales fell to KRW 5,402 million and the company swung to an operating loss of KRW 452 million and a net loss of KRW 611 million.

Sales in 2024 were KRW 5,488 million, roughly flat, but the operating loss widened to KRW 916 million and the net loss reached KRW 1,204 million, the largest of the three years. Sales in 2025 declined to KRW 3,749 million, with an operating loss of KRW 905 million and a net loss of KRW 831 million.

On a 2025 standalone basis, approved at the March 31, 2026 general shareholders' meeting, total assets were KRW 7,187 million, total liabilities KRW 5,184 million and total equity KRW 2,003 million, so liabilities well exceed equity.

In October 2024 the share price rose sharply over one week to KRW 7,850 on October 25, and the Korea Exchange designated the stock as a concentrated small-account trading stock that month.

Based on quotes as of October 1, 2026, the share price was KRW 2,670, market capitalization KRW 9.5 billion, the 52-week high KRW 4,885 and low KRW 2,000, with returns of -17.85% over three months, -22.50% over six months and -32.49% over twelve months. At the time of writing, the share price was KRW 3,000 and the market capitalization KRW 10.7 billion.

04

Outlook

The most important business variable for Bioten is whether sales can recover. Since 2023, sales have moved between KRW 3,749 million and KRW 5,488 million, so the question is whether overseas sales of its TENQmin brand and its MOUs convert into actual revenue.

How much the 2024 anti-obesity and colorectal cancer licensing agreements contribute to near-term earnings depends on clinical and regulatory progress. The completion of the new Jeongeup plant in August 2025 has added production capacity, but utilization and cost improvements have not been disclosed as figures.

Whether single-customer concentration, above 85% as of 2022, eases is another key point. With operating losses in the KRW 900 million range in both 2024 and 2025, whether cost restructuring or revenue growth comes first will shape any narrowing of losses.

With total equity reduced to KRW 2,003 million, the method and timing of any additional funding remain a variable for financial stability. The next checkpoints are the sales and operating results in the third-quarter 2026 report and the performance of overseas channels.

05

Bull factors

Licensing-driven indication expansion

In June and July 2024, the company signed technology transfer licensing agreements for anti-obesity and colorectal cancer prevention and treatment compositions, extending its scope from functional materials toward pharmaceutical indications.

A colorectal cancer clinical trial for TENQmin S Plus received IRB approval from Konyang University in July 2024. The company has stated that expanding into animal and human pharmaceuticals is its long-term goal. The timing of royalties or other revenue from these agreements depends on clinical progress.

Prior profitability and expanded production base

In 2022, sales were KRW 10,705 million and operating profit KRW 1,777 million, showing that the company once operated profitably. It bought a second plant in Yeonggwang in June 2024 and completed a new Jeongeup plant and headquarters relocation in August 2025.

These investments can be read as providing room for production capacity and cost structure improvement. The actual effect will appear in utilization and sales trends.

Overseas channels and an own brand

Its own brand TENQmin, launched in March 2023, targeted the United States, China, Vietnam and Central Asia. A December 2023 news report said four MOUs had been signed, and buyers in Vietnam and Kazakhstan had been engaged while export licensing procedures for health foods were underway. Owning a consumer brand means the business extends beyond supplying ingredients.

06

Bear factors

Three straight net losses and shrinking sales

Net losses of KRW 611 million in 2023, KRW 1,204 million in 2024 and KRW 831 million in 2025 have followed one another. Sales in 2025 were KRW 3,749 million, far below the KRW 10,705 million recorded in 2022. An operating loss of KRW 905 million shows that losses in the core business have persisted.

Shrinking equity and debt burden

On a 2025 standalone basis, total liabilities of KRW 5,184 million far exceed total equity of KRW 2,003 million. Equity stood at roughly KRW 3.3 billion in 2023, so continued losses have reduced it over time. A further decline in equity could limit the company's room and terms for additional financing.

Customer concentration and trading volatility

As of 2022, a single principal customer accounted for more than 85% of total sales.

During the 2023 listing process, a securities filing obligation arose for a capital increase that could be regarded as a deemed public offering, and because it was not fulfilled, the company came under a Financial Supervisory Service examination.

The Korea Exchange designated the stock as a concentrated small-account trading stock in October 2024, and the price on October 1, 2026 was below the KRW 8,000 listing reference price.

07

Risk factors

Macro

Health food demand is sensitive to household spending and consumer sentiment. As export exposure grows, exchange-rate swings and changes in partner-country licensing rules become earnings variables. Raw material price movements can also affect costs and margins.

Regulatory and pipeline

Health functional foods and pharmaceutical materials depend on approvals and clinical clearance, which set the pace of the business. The anti-obesity and colorectal cancer licensing pipelines remain in clinical stages, so the timing of commercialization is uncertain. Delays in approval or changes in clinical results would directly affect expected licensing income.

Market and liquidity

KONEX is an entry-stage market for young small companies before they move to KOSDAQ, and trading volume is small. The October 2024 sharp rise driven by trades among individual accounts, which led to designation as a concentrated small-account trading stock, illustrates the point. In such a market, the share price can move considerably on supply and demand factors unrelated to results.

08

Overall view

Bioten has strengths in its natural-product functional materials technology, its licensing pipeline and its own overseas brand. However, three consecutive years of net losses since 2023 and shrinking sales remain the largest bearish factors.

The profitable results of 2022 and the completion of the new Jeongeup plant in 2025 can be read as bullish arguments that the business structure could recover.

Total equity fell to KRW 2,003 million on a 2025 basis, liabilities well exceed equity, and single-customer concentration is high, which weighs on both financial and operating conditions.

Based on quotes as of October 1, 2026, the share price moved between the 52-week low of KRW 2,000 and high of KRW 4,885, and the current price of KRW 3,000 is well below the KRW 8,000 listing reference price.

Under this configuration, whether quarterly sales recover and operating losses narrow will determine which side of the bullish and bearish arguments gains weight.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. comp.fnguide.com
  2. saramin.co.kr
  3. saramin.co.kr
  4. news.nate.com
  5. markets.hankyung.com
  6. investnews.co.kr
  7. getnews.co.kr
  8. asiae.co.kr
  9. gj.newdaily.co.kr
  10. etnews.com
  11. prestocknews.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis